New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Form SC 13D/A Mersana Therapeutics, Filed by: New Enterprise Associates 14, L.P.
-
Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer
-
Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer
-
Coursera Launches Workforce Recovery Initiative for Governments Responding to the Unemployment Crisis Caused by COVID-19
-
Coursera Launches Workforce Recovery Initiative for Governments Responding to the Unemployment Crisis Caused by COVID-19
-
Bright Health Names G. Mike Mikan Chief Executive Officer; Bob Sheehy to become Executive Chairman of the Board
-
For SoftBank's Son, coronavirus turns vision to illusion
-
CIT GAP Funds Investment Director to Judge Pitch Competition at 2020 Virginia Women Veterans Summit
-
Aetion and HealthVerity Launch Integrated Real-World Evidence Solution to Assess the Safety and Effectiveness of COVID-19 Interventions
-
Form SC 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
-
Telehealth Companies Lead Digital Health to Record VC Funding in Q1 2020 with $3.6 Billion
-
Form SC 13D/A Senseonics Holdings, Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
Beyond Identity Delivers the End of Passwords
-
Silicon Valley Icons Jim Clark and Tom Jermoluk Launch “Beyond Identity”
-
Beyond Identity Delivers the End of Passwords
-
Form 4 Mersana Therapeutics, For: Apr 09 Filed by: New Enterprise Associates 14, L.P.
-
OmniSci and Z by HP Accelerate Data-Driven Workflows
-
Topia Completes Workday Approved Integration
-
Duolingo Hires Chief Financial Officer and General Counsel, Passes One Million Paid Subscribers
-
CIT GAP Funds Invests in Curbside Kitchen to Continue Connecting Building Owners and Multi-Family Properties with Food Trucks
-
Woebot Labs Adds COVID-19 Support Through its Mobile Health Chatbot
-
Woebot Labs Adds COVID-19 Support Through its Mobile Health Chatbot
-
Form SC 13D/A Ra Pharmaceuticals, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Lumos Pharma Promotes John C. McKew, PhD to Chief Operating Officer and Chief Scientific Officer
-
Lumos Pharma Promotes John C. McKew, PhD to Chief Operating Officer and Chief Scientific Officer
-
SSM Health Kidney Care begins serving patients in the St. Louis community
-
DataRobot Unveils Latest Version of Enterprise AI Platform, Introducing Visual AI, AI Applications, and Automated Deep Learning
-
OmniSci Announces Expansion to Address Growing Demand in Asia, Adds Joseph Lee as Vice President, Global Sales
-
Form SC 13D LUMOS PHARMA, INC. Filed by: New Enterprise Associates 14, L.P.
-
Tom Reilly, Former CEO of Cloudera and ArcSight, Joins OmniSci Board of Advisors
-
OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
-
Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies
-
Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies
-
Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board
-
Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board
-
CIT Recognizes Women-Led Virginia Startups During Women’s History Month
-
GigSmart Launches Health Marketplace to Provide Benefits to Independent Workers
-
CIT GAP Funds Invests in MetiStream to Improve Patient Outcomes by Addressing Healthcare Industry’s Unstructured Data Problems
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
-
Form SC 13D IMARA Inc. Filed by: New Enterprise Associates 14, L.P.
-
DataRobot Opens Up its Platform for COVID-19 Response Efforts
-
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
-
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
-
Topia Acquires Monaeo
-
CarAdvise & Stride Partner to Drive More Value in the Gig-Economy and Beyond
-
NEA Closes On $3.6B for New Fund with Focus on Early-Stage Technology and Healthcare Investments
-
2019 Full-Year Results: Significant progress in NASH, MPS VI and psoriasis, and extended cash runway
-
2019 Full-Year Results: Significant progress in NASH, MPS VI and psoriasis, and extended cash runway
-
Trillium Therapeutics Reports Annual Financial and Operating Results

